FMP
Unicycive Therapeutics, Inc.
UNCY
NASDAQ
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
0.68 USD
0.031 (4.56%)
Valuation Date:
Mar 21, 2025 4:00 PM
Share Price on Valuation Date
$0.68
Stock Beta
2.252
Shares Outstanding
103796000